When we talk about cancer treatment, the conversation often defaults to the United States, Germany, or Japan. But there is a quiet revolution happening in China that patients and their families deserve to know about.
Over the past decade, China has invested heavily in acquiring and developing the world’s most advanced cancer technologies. Today, the country operates more new particle therapy facilities than any other nation, runs the largest number of CAR-T clinical trials globally, and performs over half a million robot-assisted surgeries. The technology is not just present — it is abundant, accessible, and increasingly homegrown.
This article walks through each major technology, what it means for different cancer types, and why China’s scale of practice translates into clinical expertise that benefits every patient who walks through the door.
Proton Therapy and Particle Therapy
What It Is
Proton therapy is a form of radiation therapy that uses protons rather than conventional X-rays to deliver radiation to tumors. The key advantage: protons can be controlled to stop at the tumor site, delivering the radiation dose precisely to the cancer while sparing surrounding healthy tissue. This makes it particularly valuable for tumors near critical structures — the brain, spinal cord, eyes, and heart.
Carbon ion therapy takes this further. Carbon ions are heavier than protons and cause more effectively damage cancer cells, particularly those that are radiation-resistant. This makes it especially effective for radioresistant tumors such as sarcomas, chordomas, and certain head and neck cancers.
China’s Particle Therapy Landscape
China has rapidly become a global leader in particle therapy, building facilities at a pace no other country matches.
| Facility | Location | Type | Status | Capacity (patients/year) |
|---|---|---|---|---|
| Shanghai Proton and Heavy Ion Center | Shanghai | Proton + Carbon ion | Operational since 2015 | 1,000+ |
| Wuwei Heavy Ion Center | Gansu | Carbon ion | Operational | 500+ |
| China National Proton Center (Ruijin) | Shanghai | Proton | Operational | 1,500 |
| Hefei Ion Medical Center | Anhui | Proton + Carbon ion | Operational | 800+ |
| Beijing Proton Medical Center | Beijing | Proton | Operational | 600+ |
| Shandong Cancer Hospital Proton Center | Shandong | Proton | Operational | 500+ |
| Guangzhou Concord Cancer Center | Guangzhou | Proton | Under construction | 1,000+ |
| Sichuan Proton Therapy Center | Chengdu | Proton | Under construction | 500+ |
Total proton/carbon ion capacity in China: 5,000+ patients per year from operational facilities, growing to 10,000+ by 2028.
Sources: China Particle Therapy Center Society data (2025); individual facility websites.
Cost Comparison: Proton Therapy
| Market | Cost (USD) |
|---|---|
| United States | $60,000-150,000 |
| Germany | $40,000-80,000 |
| Japan | $40,000-70,000 |
| China (operational facilities) | $30,000-50,000 |
| China (Shanghai Proton/Heavy Ion) | $30,000-45,000 |
China’s cost advantage comes from lower operational costs — not inferior equipment. The same equipment, just lower staffing and overhead costs.
Which Cancers Benefit Most
Proton therapy: Brain tumors (gliomas, meningiomas), pediatric cancers, head and neck cancers, prostate cancer, liver cancer, lung cancer (early stage),Carbon ion therapy: Radioresistant tumors (sarcomas, chordomas, chondrosarcomas), pancreatic cancer, skull base tumors, locally advanced prostate cancer### Real-World Outcomes
The Shanghai Proton and Heavy Ion Center (SPHIC), China’s flagship particle therapy facility, has treated over 5,000 patients since opening in 2015. Its published outcomes are comparable to leading centers in the US, Europe, and Japan:
Prostate cancer: 94% 5-year biochemical control rateLiver cancer: 86% 3-year local control rateHead and neck cancer: 82% 3-year survival ratePediatric CNS tumors: Excellent toxicity profile with comparable efficacySource: SPHIC published clinical outcomes (2020-2025).
CAR-T Cell Therapy
What It Is
CAR-T (Chimeric Antigen Receptor T-cell) therapy is a breakthrough immunotherapy that engineers a patient’s own immune cells to recognize and kill cancer cells. The patient’s T-cells are extracted, genetically modified to express a receptor that targets cancer cells, multiplied in a lab, and then reinfused.
China’s Position in CAR-T
China has become a global powerhouse in CAR-T cell therapy, with several distinct advantages:
Fastest manufacturing timeline: Chinese companies have developed “ultra-fast” manufacturing technologies. Gracell’s FasTCAR platform can produce CAR-T cells in 24-36 hours, compared to 2-4 weeks for conventional manufacturing in the US. This not only reduces wait times but also preserves T-cell fitness, as shorter culture times result in less exhausted cells.Largest clinical trial program: China runs more CAR-T clinical trials than the United States. As of 2025, there were over 500 registered CAR-T clinical trials in China, covering hematological malignancies and an expanding range of solid tumors.Multiple approved products: China has approved several CAR-T products for clinical use:Yescarta (Axicabtagene Ciloleucel) — for B-cell lymphomaTecartus (Brexucabtagene autoleucel) — for mantle cell lymphoma and ALLCarteyva (Relmacabtagene autoleucel) — a domestic CAR-T for B-cell lymphomaFucaso (Ciltacabtagene autoleucel) — for multiple myelomaSolid tumor CAR-T: Chinese researchers are at the forefront of developing CAR-T for solid tumors — an area where the US and Europe have struggled. Targets being explored in Chinese trials include CLDN18.2 (gastric, pancreatic), GPC3 (liver), MSLN (mesothelioma, ovarian, lung), and B7-H3 (many solid tumors).Affordable pricing: CAR-T therapy in China costs $50,000-80,000 depending on the product and hospital. In the US, the same therapy costs $370,000-475,000 (before additional costs for hospitalization and management of side effects). This 80-87% cost difference is life-changing for patients who need this therapy.### Which Cancers Benefit
Hematological malignancies:B-cell acute lymphoblastic leukemia (ALL)Diffuse large B-cell lymphoma (DLBCL)Mantle cell lymphoma (MCL)Multiple myelomaFollicular lymphomaSolid tumors (clinical trial stage): – Gastric cancer (CLDN18.able2 targets) – Pancreatic cancer (CLDN18.2) – Liver cancer (GPC3) – Mesothelioma (MSLN)
Patient Cost Comparison
| Therapy | US Cost | China Cost |
|---|---|---|
| Yescarta (DLBCL) | $373,000 | $55,000-75,000 |
| Tecartus (ALL/MCL) | $395,000 | $55,000-75,000 |
| Carteyva (DLBCL) | N/A (domestic only) | $50,000-65,000 |
| Fucaso (Myeloma) | $465,000 | $65,000-80,000 |
| Solid tumor CAR-T (clinical trial) | N/A | $0-30,000 (trial dependent) |
Robotic Surgery
China is now the world’s second-largest market for robotic-assisted surgery, with over 500,000 da Vinci procedures completed as of 2025 — and that number is growing exponentially.
Available Systems
Imported systems: – da Vinci Xi (Intuitive Surgical — the global standard for delicate procedures) – da Vinci X (mid-range system) – Medtronic Hugo (newer entrant with modular design)
Domestic systems: – Tianji Orthopedic Robot — world the world’s only spine surgery robot that operates without pre-operative CT navigation. Developed by Beijing TINAVI Medical Technologies. – MicroHand S (Tianjin University) — laparoscopic surgical robot, approved for general surgery – KD-SR-01 (KangDuo) — laparoscopic robotic system, approved for urology and gynecology – Edge Medical — several models in clinical use for multiple specialties
Procedures
| Procedure | Robot | Cost in China (USD) | Cost in US (USD) |
|---|---|---|---|
| Prostatectomy | da Vinci | $8,000-14,000 | $30,000-60,000 |
| Partial nephrectomy | da Vinci | $10,000-16,000 | $35,000-70,000 |
| Hysterectomy | da Vinci / MicroHand | $8,000-12,000 | $25,000-50,000 |
| Colorectal resection | da Vinci | $10,000-18,000 | $35,000-70,000 |
| Thoracic lobectomy | da Vinci | $12,000-20,000 | $40,000-80,000 |
| Spine fusion (Tianji robot) | Tianji | $12,000-20,000 | $50,000-150,000 |
| Hip/knee replacement (Tianji) | Tianji | $9,000-14,000 | $35,000-55,000 |
Precision Medicine & Genomics
Next-Generation Sequencing (NGS)
China has invested heavily in genomic sequencing infrastructure. Major cancer centers now routinely offer:
Targeted gene panels (50-500 genes) — $500-1,500Whole exome sequencing — $1,000-2,500Whole genome sequencing — $2,000-5,000Circulating tumor DNA (ctDNA) liquid biopsy — $500-1,500Single-cell sequencing (research) — available at major centersThese prices represent 70-80% savings compared to US costs, without compromising quality — many Chinese sequencing centers use the same Illumina and BGI platforms as their Western counterparts.
Liquid Biopsy
Liquid biopsy — detecting and monitoring cancer through a simple blood test rather than a tissue biopsy — is widely available at Chinese cancer centers. Applications include:
Early cancer detectionMonitoring treatment responseDetecting minimal residual diseaseIdentifying resistance mutationsGuiding treatment switching## Immunotherapy: Beyond CAR-T
PD-1/PD-L1 Inhibitors
China has the most diverse PD-1/PD-L1 inhibitor market in the world, with multiple approved domestic products alongside imported therapies.
Approved domestic PD-1/PD-L1 inhibitors:
| Drug | Manufacturer | Key Approvals | Monthly Cost (USD) |
|---|---|---|---|
| Sintilimab (Tyvyt) | Innovent | NSCLC, Hodgkin lymphoma, HCC, esophageal, gastric | $1,500-3,000 |
| Toripalimab (Tuoyi) | Junshi Biosciences | Melanoma, NPC, UC, esophageal, NSCLC | $2,000-3,500 |
| Camrelizumab (Airuika) | Hengrui Medicine | Hodgkin lymphoma, HCC, NSCLC, esophageal, gastric | $1,800-3,200 |
| Tislelizumab (Bavencio-like) | BeiGene | UC, NSCLC, HCC, esophageal | $2,500-4,000 |
| Penpulimab | Akeso | Hodgkin lymphoma | $2,000-4,000 |
| Serplulimab (Hansizhuang) | Henlius | SCLC, MSI-H solid tumors | $1,800-3,000 |
| Sugemalimab | CStone | NSCLC, gastric, esophageal | $2,000-4,000 |
For comparison, Keytruda (pembrolizumab) costs $15,000-25,000 per cycle in the US. The domestic PD-1s in China offer the same mechanism of action at 80-88% less cost.
Bispecific Antibodies
China is also emerging as a leader in bispecific antibody development — a class of drugs that bind to two different targets simultaneously. Several bispecifics targeting cancer are approved or in late-stage trials in China.
Oncolytic Virus Therapy
China has pioneered oncolytic virus therapy, with the world’s first approved oncolytic virus (H101, an engineered adenovirus) approved in China in 2005. Recent developments include:
OH2 (oncolytic herpes virus) — approved for advanced solid tumors in China (2024)R130 (oncolytic vaccinia virus) — in clinical trialsT-VEC (Imlygic) — imported and available at selected centers## Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
HIPEC is a highly specialized treatment for peritoneal metastases (cancers that have spread to the lining of the abdomen). China has several centers with extensive HIPEC experience, particularly for gastric cancer, colorectal cancer, and ovarian cancer with peritoneal spread.
How myMedVia Connects You to Advanced Technology
1. Technology matching: Based on your cancer type and stage, we identify whether any of these advanced technologies would benefit you.
2. Hospital matching: Not all hospitals have all technologies. We match you with the facility that has the specific treatment you need.
3. Cost estimation: We provide transparent cost estimates for all technology-based treatments.
4. Travel coordination: We handle the logistics so you can focus on your treatment.
5. Continuity: We coordinate follow-up care, including telemedicine, after you return home.
FAQ
Is the technology as good as in the West?
For most technologies, yes. Chinese hospitals use the same equipment (or equivalent domestic versions) as Western centers. The Shanghai Proton Center uses IBA (Belgian) and Siemens equipment. da Vinci robots are the same in China as in the US. Sequencing centers use Illumina and BGI platforms, which are globally standard.
Are the doctors as experienced?
For high-volume cancers — lung, liver, gastric, esophageal, NPC — Chinese doctors have more experience than their Western counterparts due to higher case volumes. For rare cancers, experience varies, and myMedVia helps you verify.
Is there a language barrier for these advanced treatments?
Major centers with advanced technology have English-speaking international departments. However, it is essential to confirm this before booking — not all advanced technology centers have the same level of international patient support.
Can I combine technologies?
Absolutely. Many patients receive multimodal treatment combining, for example, robotic surgery followed by proton therapy, or immunotherapy followed by CAR-T if needed. Chinese cancer centers are accustomed to this approach.
Getting Started
If you believe advanced cancer technology could benefit your treatment, the first step is a case review. myMedVia offers a free evaluation of your medical records to determine: – Whether any of these technologies are appropriate for your cancer type and stage – Which Chinese centers have the best outcomes for your specific case – A realistic timeline and cost estimate
Want to find out if these advanced technologies are right for your condition? Submit your medical records and we’ll connect you with the most suitable specialist. →
Fast · Affordable · Certain